Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $20.14

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.14.

Several analysts have issued reports on ACRV shares. LADENBURG THALM/SH SH decreased their price objective on shares of Acrivon Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, April 5th. JMP Securities restated a “market outperform” rating and set a $14.00 price objective on shares of Acrivon Therapeutics in a report on Monday, April 1st. BMO Capital Markets reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of Acrivon Therapeutics in a research report on Monday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Acrivon Therapeutics in a research report on Thursday, March 28th.

Insider Transactions at Acrivon Therapeutics

In other news, major shareholder Perceptive Advisors Llc acquired 2,353,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $8.50 per share, for a total transaction of $20,000,500.00. Following the completion of the acquisition, the insider now directly owns 5,360,858 shares of the company’s stock, valued at approximately $45,567,293. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

A hedge fund recently raised its stake in Acrivon Therapeutics stock. Exchange Traded Concepts LLC increased its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,289 shares of the company’s stock after acquiring an additional 3,370 shares during the quarter. Exchange Traded Concepts LLC owned about 0.06% of Acrivon Therapeutics worth $65,000 as of its most recent SEC filing. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

NASDAQ ACRV opened at $9.51 on Friday. The business’s 50 day moving average price is $6.22 and its 200-day moving average price is $5.29. Acrivon Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $14.30. The company has a market cap of $215.31 million, a P/E ratio of -3.48 and a beta of 1.93.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). As a group, equities analysts predict that Acrivon Therapeutics will post -3.42 EPS for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.